AI Engines For more Details: Perplexity Kagi Labs You
Depression: Nortriptyline is FDA-approved for the treatment of major depressive disorder. It works by increasing the levels of certain neurotransmitters, such as serotonin and norepinephrine, in the brain, which helps to alleviate depressive symptoms. Nortriptyline may improve mood, energy levels, appetite, and sleep patterns in individuals with depression.
Neuropathic Pain: Nortriptyline is sometimes prescribed off-label for the management of neuropathic pain conditions, such as diabetic neuropathy, postherpetic neuralgia (pain following shingles), and chronic neuropathic pain syndromes. It may help reduce pain intensity and improve pain tolerance in some individuals.
Migraine Prophylaxis: Nortriptyline is also used off-label for the prevention of migraines and tension-type headaches. It may help reduce the frequency and severity of migraine attacks in certain patients. The exact mechanism by which nortriptyline exerts its prophylactic effect on migraines is not fully understood but may involve its ability to modulate pain pathways in the brain.
Anxiety Disorders: While nortriptyline is primarily indicated for depression, it may also have some efficacy in the treatment of anxiety disorders, such as generalized anxiety disorder (GAD) and panic disorder. It can help alleviate symptoms of anxiety, such as excessive worry, nervousness, and panic attacks, although it is not typically considered a first-line treatment for these conditions.
Insomnia: Some individuals with depression or anxiety may experience sleep disturbances such as insomnia. Nortriptyline's sedative properties may help improve sleep quality and duration in these patients, although it should be used cautiously in individuals with sleep apnea or other sleep-related disorders.
Other Conditions: Nortriptyline may have additional off-label uses, such as in the management of certain eating disorders, attention-deficit/hyperactivity disorder (ADHD), and irritable bowel syndrome (IBS), although the evidence supporting its efficacy in these conditions is limited.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.6 | 0.3 | 1 |
| ADHD | 2.4 | 0.9 | 1.67 |
| Allergic Rhinitis (Hay Fever) | 1.5 | 1.1 | 0.36 |
| Allergies | 2.9 | 3.2 | -0.1 |
| Allergy to milk products | 1.9 | 1.2 | 0.58 |
| Alopecia (Hair Loss) | 0.3 | 0.3 | |
| Alzheimer's disease | 4.4 | 4.4 | 0 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.5 | 1 | 2.5 |
| Ankylosing spondylitis | 3.4 | 1.2 | 1.83 |
| Anorexia Nervosa | 0.9 | 1.7 | -0.89 |
| Antiphospholipid syndrome (APS) | 0.4 | 0.3 | 0.33 |
| Asthma | 2.8 | 2.1 | 0.33 |
| Atherosclerosis | 1.8 | 0.5 | 2.6 |
| Atrial fibrillation | 2.6 | 2.7 | -0.04 |
| Autism | 5.9 | 6.6 | -0.12 |
| Autoimmune Disease | 1.2 | 0.3 | 3 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 0.8 | 0.8 | |
| Bipolar Disorder | 1.8 | 1.2 | 0.5 |
| Brain Trauma | 0.9 | 0.9 | 0 |
| Breast Cancer | 0.2 | 0.2 | |
| Cancer (General) | 0.6 | 0.6 | 0 |
| Carcinoma | 3 | 1.2 | 1.5 |
| Celiac Disease | 1.3 | 2.2 | -0.69 |
| Cerebral Palsy | 1.5 | 0.6 | 1.5 |
| Chronic Fatigue Syndrome | 3.4 | 3.7 | -0.09 |
| Chronic Kidney Disease | 1.9 | 2.1 | -0.11 |
| Chronic Lyme | 0 | 0.3 | 0 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.3 | 1.4 | -0.08 |
| Chronic Urticaria (Hives) | 1.3 | 1.5 | -0.15 |
| Coagulation / Micro clot triggering bacteria | 1 | 0.6 | 0.67 |
| Cognitive Function | 1.5 | 0.6 | 1.5 |
| Colorectal Cancer | 4.3 | 1.5 | 1.87 |
| Constipation | 1.6 | 1.6 | |
| Coronary artery disease | 1.8 | 1.7 | 0.06 |
| COVID-19 | 4.5 | 6.1 | -0.36 |
| Crohn's Disease | 4.8 | 4.5 | 0.07 |
| Cushing's Syndrome (hypercortisolism) | 0.4 | -0.4 | |
| cystic fibrosis | 0.7 | 0.6 | 0.17 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2 | 0.9 | 1.22 |
| Denture Wearers Oral Shifts | 0.6 | 0.6 | |
| Depression | 6.1 | 6.2 | -0.02 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.5 | 0.9 | 0.67 |
| Endometriosis | 1.8 | 1.3 | 0.38 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 2.7 | 1.5 | 0.8 |
| erectile dysfunction | 1.2 | 0.3 | 3 |
| Fibromyalgia | 0.6 | 2.3 | -2.83 |
| Functional constipation / chronic idiopathic constipation | 3.1 | 2.2 | 0.41 |
| gallstone disease (gsd) | 1.5 | 0.9 | 0.67 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | 0.6 | 0.67 |
| Generalized anxiety disorder | 2.5 | 1.6 | 0.56 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.4 | 1 | 0.4 |
| Graves' disease | 1.5 | 2 | -0.33 |
| Gulf War Syndrome | 0.6 | 1.5 | -1.5 |
| Halitosis | 1.2 | 0.3 | 3 |
| Hashimoto's thyroiditis | 2.1 | 1.5 | 0.4 |
| Heart Failure | 2.6 | 1.6 | 0.63 |
| hemorrhagic stroke | 0.3 | 0.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 0.1 | 0.6 | -5 |
| hypercholesterolemia (High Cholesterol) | 0.1 | 0.6 | -5 |
| hyperglycemia | 1.5 | 1.5 | 0 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.6 | -0.6 | |
| hypertension (High Blood Pressure | 3.3 | 3.1 | 0.06 |
| Hypothyroidism | 0.9 | 0.9 | 0 |
| Hypoxia | 1.6 | 1 | 0.6 |
| IgA nephropathy (IgAN) | 1.5 | 2.4 | -0.6 |
| Inflammatory Bowel Disease | 4.3 | 6 | -0.4 |
| Insomnia | 1.3 | 2.7 | -1.08 |
| Intelligence | 1 | 0.7 | 0.43 |
| Intracranial aneurysms | 0.9 | 0.9 | 0 |
| Irritable Bowel Syndrome | 3.7 | 3.9 | -0.05 |
| ischemic stroke | 2 | 1.2 | 0.67 |
| Liver Cirrhosis | 4.4 | 4 | 0.1 |
| Long COVID | 4.6 | 3.8 | 0.21 |
| Low bone mineral density | 0.6 | -0.6 | |
| Lung Cancer | 1 | 0.9 | 0.11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1 | 0.9 | 0.11 |
| ME/CFS with IBS | 0.4 | 1.2 | -2 |
| ME/CFS without IBS | 1.1 | 0.6 | 0.83 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.6 | 0.4 | 0.5 |
| Metabolic Syndrome | 4.6 | 4.5 | 0.02 |
| Mood Disorders | 6.7 | 5.9 | 0.14 |
| multiple chemical sensitivity [MCS] | 1 | 1 | |
| Multiple Sclerosis | 4.6 | 3.6 | 0.28 |
| Multiple system atrophy (MSA) | 1 | 0.6 | 0.67 |
| myasthenia gravis | 0.9 | 0.9 | |
| neuropathic pain | 0.3 | 1.3 | -3.33 |
| Neuropathy (all types) | 0.9 | 0.6 | 0.5 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.2 | 3.1 | 0.03 |
| NonCeliac Gluten Sensitivity | 1.8 | 0.6 | 2 |
| Obesity | 6 | 5.1 | 0.18 |
| obsessive-compulsive disorder | 2.8 | 2.7 | 0.04 |
| Osteoarthritis | 1.5 | 1.5 | 0 |
| Osteoporosis | 1.8 | 1.2 | 0.5 |
| pancreatic cancer | 0.4 | 0.3 | 0.33 |
| Parkinson's Disease | 4.8 | 4.7 | 0.02 |
| Polycystic ovary syndrome | 2.8 | 1.9 | 0.47 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.6 | 0.6 | |
| primary biliary cholangitis | 0.6 | 1.2 | -1 |
| Primary sclerosing cholangitis | 1.3 | 0.6 | 1.17 |
| Psoriasis | 1.9 | 2.4 | -0.26 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.6 | 2.6 | 0.77 |
| Rosacea | 0.6 | 0.3 | 1 |
| Schizophrenia | 4.4 | 2.1 | 1.1 |
| scoliosis | 0.4 | 1.2 | -2 |
| Sjögren syndrome | 1.9 | 1.2 | 0.58 |
| Sleep Apnea | 1.5 | 1.2 | 0.25 |
| Slow gastric motility / Gastroparesis | 1 | 0.3 | 2.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.1 | 14 |
| Stress / posttraumatic stress disorder | 1.3 | 2.2 | -0.69 |
| Systemic Lupus Erythematosus | 3.4 | 0.9 | 2.78 |
| Tic Disorder | 0.7 | 1.2 | -0.71 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 3.5 | 2.1 | 0.67 |
| Type 2 Diabetes | 4.9 | 4.2 | 0.17 |
| Ulcerative colitis | 2.7 | 4 | -0.48 |
| Unhealthy Ageing | 2.7 | 1.5 | 0.8 |
| Vitiligo | 1.7 | 1.3 | 0.31 |
